ATH 12.5% 0.4¢ alterity therapeutics limited

the role of transition metals & ..., page-2

  1. 5,886 Posts.
    lightbulb Created with Sketch. 150
    Nice find finito, liked the conclusion.
    [. Through thorough research into this area, current drug trials target memory deficit in early – moderate Alzheimer’s However it is questionable whether this is too late. Consideration of executive function and early treatment of AD; a cure may be possible or at least consequences are more reversible. PBT2 not only detoxifies the harmful Aß plaques but also re-establishes homeostasis of metals at a stage where neuronal death hasn’t yet occurred. Clinical trials for PBT2 Phase IIb will hopefully provide promising results for curing AD. ]
    Who was that? Med student.
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.4¢
Change
-0.001(12.5%)
Mkt cap ! $18.62M
Open High Low Value Volume
0.4¢ 0.4¢ 0.4¢ $7.902K 2.037M

Buyers (Bids)

No. Vol. Price($)
40 53603756 0.3¢
 

Sellers (Offers)

Price($) Vol. No.
0.4¢ 126995306 20
View Market Depth
Last trade - 14.03pm 15/08/2024 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.